Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Community study demonstrates Keppra’s use in various pain types

21.03.2003


New data shows that the antiepileptic drug Keppra (levetiracetam), when used alone and in combination with other treatments, provided relief to more than 90 percent of patients with a range of pain syndromes, from migraine headaches to neck and back pain. The study of 400 patients, conducted by the Statesville Pain Associates of Statesville, N.C., was presented today at the American Pain Society’s 22nd Annual Scientific Meeting.



"To date, studies of Keppra to treat pain have been conducted in small patient populations only. Our study of hundreds of patients showed that Keppra was well tolerated and has the potential to be an effective pain treatment alone or in combination with gabapentin, the current ’gold standard’ for the treatment of neuropathic pain," said Douglas Pritchard, M.D., pain specialist and lead investigator of the study. "As pain specialists, we’re always searching for more treatment options. It’s been encouraging to see this response to treatment in such a wide variety of pain states."

Each year chronic pain affects 70 million Americans, or approximately one in every four people, and contributes to 40 million doctor visits. The burden of pain also results in 515 million lost workdays, and accounts for $100 billion in medical expenses each year.1


Investigators determined that 372 of 400 patients involved in the study responded to Keppra, currently approved by the U.S. Food and Drug Administration for the adjunctive treatment of partial onset seizures in adults. Keppra was given as a stand-alone treatment or in combination with gabapentin, another antiepileptic drug (AED) used to treat pain, to 400 patients experiencing migraine headaches, neck, back, nerve, diabetic and complex regional pain syndromes.

This retrospective analysis was of 400 patients given Keppra over a six-month period as a stand-alone drug (n=30%) and in combination with gabapentin (n=70%). Five percent of the patients in this study were treated for migraine headaches and the others were treated for various types of pain including, neck pain (20%), back pain (40%), nerve pain (15%), diabetic pain (15%) and complex regional pain syndromes (5%). Keppra was titrated to dosages between 1,000 and 2,000 mg/day, throughout the duration of treatment (one to six months).

Participants also evaluated their own pain using the visual analog scale (VAS), in which pain is evaluated on a scale of 0-10, with 10 signifying the highest degree of pain. Before starting treatment with Keppra, patients rated their pain between 7 and 10, but within five to 10 days, their self-evaluated VAS scores fell to 5 and 6. The patients’ pain relief was also evaluated by a patient global assessment of pain indicating good pain relief as well as improved function and quality of life.

The most common side effects associated with the use of Keppra in this analysis were drowsiness and nausea.


About Statesville Pain Associates
The pain management team at Statesville Pain Associates strives to minimize patients’ pain, restore their ability to function and ultimately enable them to enjoy a better quality of life. Headed by Dr. Douglas Pritchard and Dr. Bobby Kearney, Statesville Pain Associates treats over 800 patients a month using a multidimensional and a multidisciplinary approach.

Jessica Balaban | EurekAlert!
Further information:
http://www.ncps-cpr.com

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

UCLA engineers use deep learning to reconstruct holograms and improve optical microscopy

22.11.2017 | Medical Engineering

Watching atoms move in hybrid perovskite crystals reveals clues to improving solar cells

22.11.2017 | Materials Sciences

New study points the way to therapy for rare cancer that targets the young

22.11.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>